







Yep, May 4th – 8th is Clinical Trial Awareness Week, and you know how I feel about clinical trials! I have to admit, two years ago I would have said “it’s what week” but then I received the ‘Diagnosis’ and now I am an advocate for clinical trial participation and for the need to bring the patient to the table with the researcher so all of our needs are met. Amazing how life changes isn’t it?
Regular readers are aware that almost every post, no matter the topic, includes a push for you to sign up for the Fox Trial Finder. But then what? You say “OK Tom” and you sign up and you get your first list of trials that match your information and you are excited to find the perfect match that will lead to the cure! But…if you are like me, you discover that you don’t qualify for your first choice because you are already taking Sinemet or Mirapex or some other PD drug. Oh and that is the same problem with your second choice too!
Oh look, a soap box….
I have written about this problem before and it was discussed it at the Rally for the Challenge last year in Grand Rapids and we have discussed it with other PwP’s but we haven’t found an answer to this problem. I may be wrong, but I believe that this issue is a major reason PD researchers can’t recruit enough trial participants. Most of the people I have talked to were diagnosed by completing the toe-heel tapping, finger tapping, nose touching etc. tests AND then, to make sure, prescribed a dopamine replacement drug. Presto, no longer eligible for many trials, at least while in the early progression of PD.
I realize that part of the reason for not taking volunteers who are already medicated is the need to make sure it is the tested drug that produces the expected improvement, not the combination of two or more drugs. But, what if the combination produces a better result? Already many of us take two or more drugs to treat all of our symptoms and improve our quality of life. So here’s my idea..
Why not include some already medicated volunteers in the study design? For example, if you need 400 subjects for Phase III, how about 300 who aren’t taking a dopamine replacement drug (if you can find them) and 50 taking Sinement and 50 taking Mirapex? It might require some tweaking of the dosage of the drugs but you have another 100 participants in your trial. Just a thought, we need clinical trials and they need volunteers, so it’s time to stop saying ‘That’s the way we have always done it” and time to be innovative and try something new.
…..OK, off the soapbox.


We arrived early to help with the setup for the walk and I was glad my stepson, Darrin, joined us for the heavy lifting! This was also our first ‘gig’ as Fox Trial Finder Ambassadors and we set up a table to promote Fox Trial Finder and Fox InSight. We had a lot of activity at our table, handed out a lot of information and MJFF orange brain shaped stress relievers. We met a lot of new people who were interested in both programs and hopefully our efforts result in some new sign ups.
We were asked to speak during the prerace ceremonies so, in addition to our first Trial Finder gig, I made my first presentation about current research and the need for participating in Fox Trial Finder and Fox InSight. I had prepared some notes (about 7 pages when printed in large type!) but found it hard to read the notes, maintain some eye contact, speak loudly AND hold the microphone at the same time so it was more of an ‘off the cuff’ speech it but it seemed to go OK for a first attempt.
Well, setting a goal of publishing a new post within two weeks of my last post didn’t quite work. Despite my best intentions and adding a reminder to my calendar, I still missed the date by, oh let’s say 2 (OK 3) weeks. Back in the days before retirement, I used a system called the Franklin Planner to plan out everyday, so maybe I need to do something similar now – NOT! While it was an interesting (and expensive) planning system complete with training on how to use, fancy binders and custom calendar pages, I still missed a goal or two and I was quite happy to discard the entire system upon retirement. But enough excuses, I’ll just chalk this one up as a learning experience and remember to not promise any deliverables.😀
What I did promise last post was that this post would cover some of the latest news about PD and I will stick to that deliverable. One of the new blogs that I now follow is The Science of Parkinson’s . If you haven’t already discovered this site, click on the link to view the site and sign up for posts. This site is the first I’ve found that does a superb job of taking the latest scientific publications and breaking it down to plain, understandable english. The author is Simon Stott, and he has been working in the field of Parkinson’s disease research for over 15 years (both in academia and biotech).
Each month, he publishes a Monthly Research Review in addition to his posts about a single research topic. You can view the June 2018 review here. This month there have been several great posts about the latest research and all in a readable and understandable format. The top story this month has been the report that researchers have found that graphene dots may prevent alpha synuclein from clumping, and even better, they appear to cause the clumps already formed to break up and disappear! I realize I threw out some new scientific words but if you go to the article here, you will get a full description of alpha synuclein and graphene dots and more. (At least I didn’t use the actual title of the research report – Graphene Quantum Dots Appear to Prevent α-synucleinopathy in Parkinson’s disease)
So it appears these graphene dots stop the clumping of alpha synuclein and break up the existing clumps in the mouse model of PD which is a great step forward. As always though, we have to hope the research results are the same (or better) when they conduct clinical trials on current patients.
And speaking of clinical trials, if you haven’t signed up for the Fox Insight study, please go here and join us in the largest longitudinal study of PD and the impact it has on each patient. If you didn’t see the Micheal J Fox interview with Jane Pauly regarding the Fox Insight study a few weeks ago, you can view it here.
In the other news category, the Parkinson’s Foundation has released it’s Parkinson’s Prevalence Project results which predicts there will be over 930,000 PD patients in the US and Canada by 2020 and 1.2 million by 2030. They also show the prevalence by state along with many other statistics. You can view the summary study here. Interesting findings and this study will hopefully help our efforts for more funding for PD research.
And finally, when I contacted Simon Stott about his website, he recommended some other sites that I found interesting so I have updated my blog list page with those sites, Simon’s site and a new category of sites, PD News Aggregators.
As always,thanks for reading.
Well, setting a goal of publishing a new post within two weeks of my last post didn’t quite work. Despite my best intentions and adding a reminder to my calendar, I still missed the date by, oh let’s say 2 (OK 3) weeks. Back in the days before retirement, I used a system called the Franklin Planner to plan out everyday, so maybe I need to do something similar now – NOT! While it was an interesting (and expensive) planning system complete with training on how to use, fancy binders and custom calendar pages, I still missed a goal or two and I was quite happy to discard the entire system upon retirement. But enough excuses, I’ll just chalk this one up as a learning experience and remember to not promise any deliverables.😀
What I did promise last post was that this post would cover some of the latest news about PD and I will stick to that deliverable. One of the new blogs that I now follow is The Science of Parkinson’s . If you haven’t already discovered this site, click on the link to view the site and sign up for posts. This site is the first I’ve found that does a superb job of taking the latest scientific publications and breaking it down to plain, understandable english. The author is Simon Stott, and he has been working in the field of Parkinson’s disease research for over 15 years (both in academia and biotech).
Each month, he publishes a Monthly Research Review in addition to his posts about a single research topic. You can view the June 2018 review here. This month there have been several great posts about the latest research and all in a readable and understandable format. The top story this month has been the report that researchers have found that graphene dots may prevent alpha synuclein from clumping, and even better, they appear to cause the clumps already formed to break up and disappear! I realize I threw out some new scientific words but if you go to the article here, you will get a full description of alpha synuclein and graphene dots and more. (At least I didn’t use the actual title of the research report – Graphene Quantum Dots Appear to Prevent α-synucleinopathy in Parkinson’s disease)
So it appears these graphene dots stop the clumping of alpha synuclein and break up the existing clumps in the mouse model of PD which is a great step forward. As always though, we have to hope the research results are the same (or better) when they conduct clinical trials on current patients.
And speaking of clinical trials, if you haven’t signed up for the Fox Insight study, please go here and join us in the largest longitudinal study of PD and the impact it has on each patient. If you didn’t see the Micheal J Fox interview with Jane Pauly regarding the Fox Insight study a few weeks ago, you can view it here.
In the other news category, the Parkinson’s Foundation has released it’s Parkinson’s Prevalence Project results which predicts there will be over 930,000 PD patients in the US and Canada by 2020 and 1.2 million by 2030. They also show the prevalence by state along with many other statistics. You can view the summary study here. Interesting findings and this study will hopefully help our efforts for more funding for PD research.
And finally, when I contacted Simon Stott about his website, he recommended some other sites that I found interesting so I have updated my blog list page with those sites, Simon’s site and a new category of sites, PD News Aggregators.
As always,thanks for reading.
Well, setting a goal of publishing a new post within two weeks of my last post didn’t quite work. Despite my best intentions and adding a reminder to my calendar, I still missed the date by, oh let’s say 2 (OK 3) weeks. Back in the days before retirement, I used a system called the Franklin Planner to plan out everyday, so maybe I need to do something similar now – NOT! While it was an interesting (and expensive) planning system complete with training on how to use, fancy binders and custom calendar pages, I still missed a goal or two and I was quite happy to discard the entire system upon retirement. But enough excuses, I’ll just chalk this one up as a learning experience and remember to not promise any deliverables.😀
What I did promise last post was that this post would cover some of the latest news about PD and I will stick to that deliverable. One of the new blogs that I now follow is The Science of Parkinson’s . If you haven’t already discovered this site, click on the link to view the site and sign up for posts. This site is the first I’ve found that does a superb job of taking the latest scientific publications and breaking it down to plain, understandable english. The author is Simon Stott, and he has been working in the field of Parkinson’s disease research for over 15 years (both in academia and biotech).
Each month, he publishes a Monthly Research Review in addition to his posts about a single research topic. You can view the June 2018 review here. This month there have been several great posts about the latest research and all in a readable and understandable format. The top story this month has been the report that researchers have found that graphene dots may prevent alpha synuclein from clumping, and even better, they appear to cause the clumps already formed to break up and disappear! I realize I threw out some new scientific words but if you go to the article here, you will get a full description of alpha synuclein and graphene dots and more. (At least I didn’t use the actual title of the research report – Graphene Quantum Dots Appear to Prevent α-synucleinopathy in Parkinson’s disease)
So it appears these graphene dots stop the clumping of alpha synuclein and break up the existing clumps in the mouse model of PD which is a great step forward. As always though, we have to hope the research results are the same (or better) when they conduct clinical trials on current patients.
And speaking of clinical trials, if you haven’t signed up for the Fox Insight study, please go here and join us in the largest longitudinal study of PD and the impact it has on each patient. If you didn’t see the Micheal J Fox interview with Jane Pauly regarding the Fox Insight study a few weeks ago, you can view it here.
In the other news category, the Parkinson’s Foundation has released it’s Parkinson’s Prevalence Project results which predicts there will be over 930,000 PD patients in the US and Canada by 2020 and 1.2 million by 2030. They also show the prevalence by state along with many other statistics. You can view the summary study here. Interesting findings and this study will hopefully help our efforts for more funding for PD research.
And finally, when I contacted Simon Stott about his website, he recommended some other sites that I found interesting so I have updated my blog list page with those sites, Simon’s site and a new category of sites, PD News Aggregators.
As always,thanks for reading.